
Uppsala Reports editor
@UMCGlobalSafety
After the pandemic: what were the lessons learnt for pharmacovigilance? Find out in the latest episode of the Drug Safety Matters podcast.
COVID-19 forced pharmacovigilance experts to revisit their processes to deal with unprecedented volumes of data and catch unexpected safety issues.
Elena Rocca of Oslo Metropolitan University joins Drug Safety Matters host Federica Santoro in the studio for a philosophical inquiry into the lessons to be learnt from the pandemic – and what it can teach us about the science of drug safety.
Subscribe by visiting the Drug Safety Matters website or listen in right here:
In this opinion article, Maria Mantziri and Natália Hromníková argue how contrasting examples from pharmacovigilance’s past could point to a more proactive and vital future.
Perspective / 29 June 2021
The identification of medicinal products (IDMP) standards will help make sure patients get the right medicines and make it easier to detect problems when things go wrong.
Perspective / 29 August 2022
Pharmacovigilance produces valuable safety data, but is it used to its full value, and how can primary healthcare workers make more use of PV findings in diagnosis and prescribing?
Perspective / 20 April 2022